Kodiak Sciences

Biopharma, Biotechnology, Energy · 123 employees

Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC® Platform uses molecular engineering to merge the f

Funding history

Funding Round — $160.0M — Dec 2025
Funding Round — $30.0M — May 2018
Funding Round — $34.0M — Mar 2016

Recent signals

Apr 01, 2026: Acquired Kodiak acquires Distributed Power Solutions for $587M
Dec 18, 2025: Raised $160.0M
Dec 16, 2025: SEC 8-K (1.01): On December 16, 2025, Kodiak Sciences Inc. entered into a material definitive Underwriting Agreement with J.P. Morgan Securities LLC, Jefferies LLC, Evercore Group L.L.C. and UBS Securities LLC. The agreement pertains to the public offering, issuance, and sale of 6,956,522 shares of its common stock at a public offering price of $23.00 per share, while the underwriters will purchase the shares from the Company at $21.62 per share. Additionally, the Company provided the underwriters with a 30-day option to purchase up to an additional 1,043,478 shares at the public offering price. This offering is strategic for the Company, potentially enhancing liquidity and funding for future operational needs.
Aug 04, 2025: Kodiak Gas Services Appoints Steven L. Green as Chief Commercial Officer
Apr 01, 2024: Acquired Kodiak Gas Services, Inc. completes acquisition of CSI Compressco LP to form industry's largest contract compression fleet
Dec 19, 2023: Acquired Kodiak Gas Services, Inc. To Acquire Csi Compressco Lp In An $854 Million All-Equity Transaction
May 22, 2018: Raised $30.0M
Mar 24, 2016: Raised $34.0M

See plans & pricing → Track Kodiak Sciences’s funding, hiring, and signals — with verified contacts — on Fundz.